QC
NVNO

Quadrature Capital’s enVVeno Medical NVNO Stock Holding History

Quadrature Capital’s Portfolio NVNO Stock Details NVNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,121
Closed -$119K – 1354
2024
Q4 		$119K Buy
+1,121
New +$125K ﹤0.01% 900
2024
Q2 		– Sell
-539
Closed -$103K – 1404
2024
Q1 		$103K Buy
+539
New +$96.7K ﹤0.01% 1129

Other funds holding NVNO

KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
WIM
Westside Investment Management Santa Monica, California $653M AUM 28.36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
ACM
Altium Capital Management New York $42M AUM
DIG
Dauntless Investment Group Etna, New Hampshire $151M AUM 76.14% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Quadrature Capital's NVNO Position: Q1 2025 in Review

Quadrature Capital sold out of enVVeno Medical (NVNO) in Q1 2025, closing a stake of 1,121 shares — an estimated $119K sold.

Quadrature Capital first reported a position in NVNO in Q1 2024 and held it in 2 quarters. The position peaked at $119K in Q4 2024. 30 funds tracked by Wall St. Rank hold NVNO as of Q1 2025.

  • Quadrature Capital reported no remaining enVVeno Medical position as of Q1 2025 after selling out during the quarter.
  • Quadrature Capital sold 1,121 enVVeno Medical shares in Q1 2025, an estimated $119K.
  • Quadrature Capital first reported a position in enVVeno Medical in Q1 2024 and held it in 2 quarters.
  • Quadrature Capital's enVVeno Medical position peaked at $119K in Q4 2024.
  • 30 funds tracked by Wall St. Rank held enVVeno Medical as of Q1 2025.

Based on Quadrature Capital's 13F filing for Q1 2025, filed 13 May 2025.